Deucravacitinib Phase 4 Results Reported at Maui Derm

Deucravacitinib was associated with significantly better dermatology life quality index (DLQI), clinically meaningful improvement in whole-body itch, substantial reductions in other symptoms and signs, and reductions in disease burden measured by patient global impression of severity (PGI-S) and patient global impression of change (PGI-C) for plaque psoriasis patients in a phase 4 study reported at Maui Derm Hawaii 2025.¹

ARTISTYK was a multicenter, randomized, double-blinded, placebo-controlled study of the oral, selective, allosteric tyrosine kinase 2 (TYK2) inhibitor, with April W. Armstrong, MD, as the primary author.

“Deucravacitinib demonstrated a robust efficacy and safety profile in the global phase 3 POETYK PSO-1 (NCT03624127) and POETYK PSO-2 (NCT03611751) trials in patients with moderate to severe plaque psoriasis,” the authors wrote. “ARTISTYK (NCT05701995), an ongoing phase 4 multicenter, randomized, double-blinded, placebo-controlled study, assesses the effect of deucravacitinib on quality of life (QoL) in patients with plaque psoriasis and impaired QoL treated in the community setting.”

The authors reported that, among other results, patients receiving deucravacitinib vs placebo were more likely to experience better DLQI outcomes (odds ratio [95% CI]: 3.1 [1.8, 5.5]; P < 0.0001). Additionally, significantly greater proportions of patients receiving deucravacitinib vs placebo achieved meaningful change in whole-body itch from Week 8 onward (P < 0.05). At Week 16, patients receiving deucravacitinib vs placebo were more likely to experience better PGI-S outcomes (odds ratio [95% CI]: 3.5 [1.9, 6.3]; P < 0.0001) and better PGI-C outcomes (odds ratio [95% CI]: 3.5 [1.9, 6.7]; P < 0.0001).

“While substantial proportions of patients with plaque psoriasis reported very large or extremely large impact of disease on QoL at baseline, patients receiving deucravacitinib vs placebo experienced significantly better DLQI outcomes at Week 16,” the authors concluded. “A third of these patients reported no impact of disease on QoL at Week 16 (primary endpoint).”

1. Armstrong A, Garcia-Zuazaga J, et al. Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 (TYK2) inhibitor, in patients with plaque psoriasis: patient-reported outcomes in a phase 4 multicenter, randomized, double-blinded, placebo-controlled study (ARTISTYK). Poster presented at: Maui Derm Hawaii 2025; January 20-24, 2025; Maui, Hawaii.